(Q35288837)

7 August 2017

title

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors (English)

1 reference

7 August 2017

1 reference

Yasuhito Fujisaka

1

1 reference

7 August 2017

Takayasu Kurata

2

1 reference

7 August 2017

Kaoru Tanaka

3

1 reference

7 August 2017

Toshihiro Kudo

4

1 reference

7 August 2017

Kunio Okamoto

5

1 reference

7 August 2017

Junji Tsurutani

6

1 reference

7 August 2017

Hiroyasu Kaneda

7

1 reference

7 August 2017

Isamu Okamoto

8

1 reference

7 August 2017

Masayuki Namiki

9

1 reference

7 August 2017

Chifumi Kitamura

10

1 reference

7 August 2017

Kazuhiko Nakagawa

11

1 reference

7 August 2017

language of work or name

1 reference

12 December 2014

1 reference

Investigational New Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

33

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

380-388

1 reference

Creative Commons Attribution 4.0 International

7 August 2017

copyright license

start time

12 December 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Localization of mesothelin in epithelial ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Antibody pharmacokinetics and pharmacodynamics

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Mesothelin is not required for normal mouse development or reproduction

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Application of Mesothelin Immunostaining in Tumor Diagnosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

Value of mesothelin immunostaining in the diagnosis of mesothelioma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4387254

The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-014-0196-0

Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25502863

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25502863

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25502863

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-014-0196-0

1 reference

7 August 2017

1 reference

7 August 2017

1 reference